CD19 and neoplasm: We have previously described tumor stroma-targeted FAP-4-1BBL and tumor-targeted CD19-4-1BBL antibody fusion proteins that can bind simultaneously to fibroblast activation protein (FAP) or CD19, respectively, and the co-stimulatory receptor 4-1BB/CD137 [24,25].